Skip to main content

Table 3 Complications and treatment measure of COVID-19 patients

From: Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China

 Total (n = 107)Survivors (n = 88)Non-survivors (n = 19)
Complications
 Shock22 (20.6)3 (3.4)19 (100.0)
 Acute cardiac injury12 (11.2)4 (4.5)8 (42.1)
 ARDS28 (26.2)11 (12.5)17 (89.5)
 Acute kidney injury14 (13.1)0 (0.0)14 (73.7)
 Evidence of co-infection
  Bacterial5 (4.7)1 (1.1)4 (21.1)
  Viral12 (11.2)10 (11.4)2 (10.5)
Treatment
 Antiviral therapy105 (98.1)87 (98.9)18 (94.7)
  Oseltamivir95 (88.8)77 (87.5)18 (94.7)
  Arbidol33 (30.8)33 (37.5)0 (0.0)
 Antibiotic therapy85 (79.4%)67 (76.1)18 (94.7)
 Glucocorticoid therapy62 (57.9)44 (50.0)18 (94.7)
 CRRT
 Oxygen therapy4 (3.7)0 (0.0)4 (21.1)
  Oxygen inhalation80 (74.8)78 (88.6)2 (10.5)
  Non-invasive ventilation7 (6.5)7 (8.0)0 (0.0)
  IMV alone17 (15.9)1 (1.1)16 (84.2)
  IMV plus ECMO3 (2.8)2 (2.3)1 (5.3)
  1. Data are n (%). P values indicate differences between survivors and non-survivors. P < 0.05 was considered significant
  2. ARDS acute respiratory distress syndrome, CRRT continuous renal replacement therapy, IMV invasive mechanical ventilation, ECMO extracorporeal membrane oxygenation